In older patients with unexplained hypertrophy, the default diagnosis of hypertrophic cardiomyopathy (HCM) may overlook a common culprit: transthyretin amyloid cardiomyopathy (ATTR-CM). In this AudioAbstract, Dr. Hallie Blevins explores the TTRACK study, which uncovered a striking prevalence of ATTR-CM in patients previously labeled with HCM and affirmed the real-world reliability of nuclear imaging in detecting it. Learn how imaging modalities, tracer choice, and subtle ECG or MRI findings can influence diagnostic accuracy and reshape our clinical approach.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.